Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Nature Medicine

Volumn 7, Issue 9, 2001, Pages 987-989

  Jain, R K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; IMATINIB; PICRIC ACID; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; BLOOD VESSEL DIAMETER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

BLOOD VESSELS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034796595     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0901-987     Document Type: Short Survey

References (28)

1. The next frontier of molecular medicine: Delivery of therapeutics
2. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
3. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
4. Angiogenesis in cancer and other diseases
5. A systems approach to cancer therapy
6. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
7. Barriers to drug delivery in solid tumors
8. Fractals and cancer
9. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors
10. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-VEGF/VPF antibody
11. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment
12. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions
13. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy
14. Endothelial cell death, angiogenesis, and microvascular function following castration in an androgen-dependent tumor: Role of VEGF
15. Blockade of PDGFR signaling by STIS71 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice
16. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
17. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
18. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment
19. Targeting tumor vasculature with homing peptides from phage display
20. Tumor infarction by targeting tissue factor to tumor vasculature
21. Vascular integrin α(v)β3: A new prognostic indicator in breast cancer
22. Genes expressed in human tumor endothelium
23. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
24. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma
25. Pharmacodynamic-mediated reduction of Temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470
26. Angiogenesis and oncogenesis
27. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements